Key result
Thioredoxin-1 shrinks aortic lesions ~37% in mice, driven by a shift to M2 macrophages.
Why the study?
Oxidative stress plays a key role in cardiovascular disorders, and the potential atheroprotective effects of thioredoxin-1 via macrophage phenotype modulation were investigated.
Does Thioredoxin-1 promote anti-inflammatory M2 macrophage polarization and reduce atherosclerosis in preclinical models?
Does Thioredoxin-1 promote anti-inflammatory M2 macrophage polarization and reduce atherosclerosis in preclinical models?
Absolute Event Rate: 62.8% vs 100%
p-value: p=<0.01
Thioredoxin-1 promotes anti-inflammatory M2 macrophage polarization and reduces atherosclerotic lesion area in hyperlipoproteinemic mice, suggesting a protective role against atherosclerosis.
Trx-1 merits further preclinical testing as an atherosclerosis target; leaves open any human therapeutic relevance.
OBJECTIVE: Oxidative stress is believed to play a key role in cardiovascular disorders. Thioredoxin (Trx) is an oxidative stress-limiting protein with anti-inflammatory and antiapoptotic properties. Here, we analyzed whether Trx-1 might exert atheroprotective effects by promoting macrophage differentiation into the M2 anti-inflammatory phenotype. METHODS AND RESULTS: Trx-1 at 1 μg/mL induced downregulation of p16(INK4a) and significantly promoted the polarization of anti-inflammatory M2 macrophages in macrophages exposed to interleukin (IL)-4 at 15 ng/mL or IL-4/IL-13 (10 ng/mL each) in vitro, as evidenced by the expression of the CD206 and IL-10 markers. In addition, Trx-1 induced downregulation of nuclear translocation of activator protein-1 and Ref-1, and significantly reduced the lipopolysaccharide-induced differentiation of inflammatory M1 macrophages, as indicated by the decreased expression of the M1 cytokines, tumor necrosis factor-α and monocyte chemoattractant protein-1. Consistently, Trx-1 administered to hyperlipoproteinemic ApoE2.Ki mice at 30 μg/30 g body weight challenged either with lipopolysaccharide at 30 μg/30 g body weight or with IL-4 at 500 ng/30 g body weight significantly induced the M2 phenotype while inhibiting differentiation of macrophages into the M1 phenotype in liver and thymus. ApoE2.Ki mice challenged once weekly with lipopolysaccharide for 5 weeks developed severe atherosclerotic lesions enriched with macrophages expressing predominantly M1 over M2 markers. In contrast, however, daily injections of Trx-1 shifted the phenotype pattern of lesional macrophages in these animals to predominantly M2 over M1, and the aortic lesion area was significantly reduced (from 100%±18% to 62.8%±9.8%; n=8; P<0.01). Consistently, Trx-1 colocalized with M2 but not with M1 macrophage markers in human atherosclerotic vessel specimens. CONCLUSIONS: The ability of Trx-1 to promote differentiation of macrophages into an alternative, anti-inflammatory phenotype may explain its protective effects in cardiovascular diseases. These data provide novel insight into the link between oxidative stress and cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Hadri et al. (2012) studied Atherosclerosis (n=8). Thioredoxin-1 (Trx-1) vs. Control (lipopolysaccharide alone) was evaluated on Aortic lesion area (p=<0.01). Daily injections of Thioredoxin-1 in ApoE2.Ki mice shifted lesional macrophages to an M2 phenotype and significantly reduced aortic lesion area from 100% to 62.8% (P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: